Melbourne Australia;  Starpharma Holdings Ltd (ASX: SPL; OTCQX: SPHRY) will participate in the Nomura Asia Equity Forum in Singapore.

The forum, held June 10 – 12, has attracted more than 1,500 delegates including management from 133 companies and more than 1,000 investors.  Starpharma is one of two Australian-based biotech companies to present at the forum, the other being Mesoblast.

“Starpharma welcomes this opportunity to present the company to a wider set of investors from across Asia and to build on an already strong and international institutional base,” said CEO Dr Jackie Fairley.

The presentation will provide an overview of Starpharma’s business and portfolio including:

• Starpharma’s lead product, VivaGel^® for the management of bacterial vaginosis including the first-in-class prevention of recurrence product and opportunity for symptomatic relief;
• The VivaGel^® coated condom product currently under regulatory review and licensed to Ansell and Okamoto;
• Drug delivery, including Starpharma’s dendrimer-docetaxel nanoparticle formulation; and
• its agrochemical program, including the recent partnership with Makhteshim Agan.

Download ASX Announcement: Starpharma presenting at Nomura Asian Equity Forum ( pdf file, 2MB)